A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts
Phase of Trial: Phase III
Latest Information Update: 14 Sep 2017
At a glance
- Drugs Furosemide (Primary)
- Indications Warts
- Focus Therapeutic Use
- Sponsors Cutanea Life Sciences
- 22 Aug 2017 Planned number of patients changed from 400 to 480.
- 22 Aug 2017 Planned End Date changed from 1 May 2018 to 1 Sep 2018.
- 13 Jan 2017 Status changed from not yet recruiting to recruiting.